News und Analysen
Relay Medical and Fio Corporation Announce Signing Distribution Partners in U.S. & France for the Fionet Mobile COVID-19 Testing and Tracking Platform
- Relay and Fio announce distribution partners in U.S. and France to market Fionet to pharmacies and certain other sectors
- With 10x more locations than hospitals,
Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee
Regulatory News:
Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1, 2020.
Epigenomics: Entscheidung vertagt – US-Krankenversicherung zu spät!
Entscheidung vertagt: Wie Epigenomics (WKN: A11QW5) heute Morgen informiert, hat die staatliche US-Krankenversicherung "Centers for Medicare & Medicaid Services", kurz CMS, noch keinen vorläufigen
Antibe Therapeutics to Present at Upcoming Conferences
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announced that the Company will be presenting at two conferences:
LD Micro 500 – Virtual Event
September 1, 2020 - 12:20pm (Eastern Time)
NeutriSci mit Unternehmens-Update über Vertragspartner, neue Märkte und Produktlinien
VANCOUVER, BC / 31. August 2020 / NeutriSci International Inc. („NeutriSci“ oder das „Unternehmen“) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) - ein innovatives Technologieunternehmen, das
NeutriSci Provides Corporate Update on Contract Partner, New Markets and Product Line
VANCOUVER, BC / ACCESSWIRE / August 31, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company developi
Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science
Aimmune Therapeutics Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it has entered
True Leaf meldet Update zur Einreichung des Jahresabschlusses für 2020 und des Zwischenabschlusses für das erste Quartal 2021
Vernon (British Columbia), 28. August 2020. True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FWB: TLA) („True Leaf“) informiert über den aktuellen Stand der Einreichung seiner Betriebs-
True Leaf Provides Update on Filing of Year End 2020 and First Quarter 2021 Financial Statements
Vernon, BC - August 28, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FSE: TLA) (“True Leaf” or the “Company”) is providing an update on the status of the filing of its
Abbott Laboratories: FDA-Zulassung für bahnbrechenden Corona-Test!
Der amerikanische Medizintechnik-Gigant Abbott Laboratories (WKN: 850103) war mit einem Plus von 7,85% auf 111,29 USD am Donnerstag einer der Tagesgewinner an der altehrwürdigen New York Stock
Relay Medical and Fio Corporation Launch Mobile COVID-19 Testing and Tracking Platform
- Fionet is a first-of-its-kind mobile testing platform for organizations to manage and track on-site COVID-19 testing
- Fionet Devices, usable by non-expert personnel,
Relay Medical und Fio Corporation lancieren mobile COVID-19-Test- und Trackingplattform
- Fionet ist die allererste mobile Testplattform, die es Organisationen ermöglicht, COVID-19-Tests vor Ort zu verwalten und nachzuverfolgen.
- Mit Fionet-Geräten, die
FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) approved the FoundationOne® Liquid CDx, Foundation Medicine’s comprehensive liquid biopsy test
EnWave unterzeichnet Technologieevaluierungs- und Lizenzoptionsvertrag mit führendem europäischen Snack-Unternehmen
Vancouver, B.C., 26. August 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave" oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
EnWave Signs Technology Evaluation and License Option Agreement with Leading European Snack Company
Vancouver, B.C., August 26th, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) announced
IMV to Participate at Four Upcoming Investor Conferences
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious
EnWave Corporation Refining Development of a Medical Device to Relieve COVID-19 Symptoms
Vancouver, B.C., August 25, 2020, EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), announced
EnWave Corporation Verfeinerungsentwicklung eines medizinischen Geräts zur Linderung der COVID-19-Symptome
Vancouver, B.C., 25. August 2020, Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting
Ipsen (Euronext: IPN; ADR: IPSEY) today announced results from the MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP), to be presented during
Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020. The
Navidea Biopharmaceuticals to Present at The LD 500 Virtual Investor Conference
Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced
QIAGEN führt einfach zu bedienenden, digitalen Test zum Nachweis von SARS-CoV-2-Antikörpern nach beantragter FDA-Notfallzulassung auf dem US-Markt ein
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Einführung seines neuen Access Anti-SARS-CoV-2 Total Tests auf dem US-Markt bekannt. Hierbei handelt es sich um einen einfach
QIAGEN to Launch Easy-to-Use Digital Test in the U.S. for Rapid Detection of SARS-CoV-2 Antibodies Following FDA Emergency Use Authorization
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of the new Access Anti-SARS-CoV-2 Total test, an easy-to-use digital test done on a portable device that
QIAGEN announces new Chairman of Supervisory Board
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced today a transition in the leadership of its Supervisory Board after an extraordinary meeting of the Supervisory Board and